GlassScriptPhysician profile
Amy C Izzett
NPI 1518906387
$1,728.96
in general payments reported to CMS, 2019-2025
25 companies · $863 in 2025
The $863 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $37.40 · 2023: $386 · 2024: $302 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,350.97 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $252.10 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $191.23 | 2024-2025 | Opdivo |
| Janssen Biotech, INC. | $191.22 | 2025 | Tecvayli, Darzalex, Talvey |
| Kadmon Pharmaceuticals LLC | $140.65 | 2021 | |
| Pharmacosmos Therapeutics INC. | $125.00 | 2023 | Monoferric |
| Glaxosmithkline, LLC. | $119.79 | 2024-2025 | Zejula, Jemperli, Blenrep |
| Merck Sharp & Dohme LLC | $112.87 | 2023-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $85.84 | 2023-2025 | |
| Pfizer INC. | $54.58 | 2025 | |
| Eisai INC. | $50.67 | 2025 | |
| Lilly USA, LLC | $47.95 | 2023-2025 | Verzenio, Jaypirca |
| Abbvie INC. | $42.85 | 2024-2025 | |
| Daiichi Sankyo INC. | $42.12 | 2024-2025 | Enhertu |
| Genmab U.S., INC. | $41.57 | 2023 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $31.30 | 2025 | Lynparza, Enhertu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $30.06 | 2024 | |
| Celgene Corporation | $25.10 | 2025 | Reblozyl |
| Beigene USA, INC. | $21.30 | 2022 | |
| Genzyme Corporation | $19.80 | 2023 | |
| Kyowa Kirin, INC. | $19.64 | 2023 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2025 | |
| G1 Therapeutics, INC. | $17.99 | 2023 | Cosela |
| Incyte Corporation | $16.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.84 | 2024 | |
| Ferring Pharmaceuticals INC. | $14.68 | 2024 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Izzett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.